All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @health.craft0 on TikTok · 64s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @health.craft0's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00It's the most viral weight loss drug in history.
  2. 0:02But while it melts fat, it can also paralyze your stomach,
  3. 0:05leaving food to rot inside you.
  4. 0:07It mimics a hormone called GLP1,
  5. 0:12hacking your brain to think you are full.
  6. 0:14It deliberately slows down digestion,
  7. 0:18but for some it works too well, causing gastroparesis.
  8. 0:21Your stomach literally stops moving.
  9. 0:23Food that should leave in four hours sits there for days.
  10. 0:26It begins to ferment and rot inside your body,
  11. 0:29creating sulfur gas and hardened rocks.
  12. 0:31This fermentation creates the infamous Ozempic burps,
  13. 0:36nasty sulfur gas that smells like rotten eggs because food.
  14. 0:40It's a nightmare for anesthesiologists.
  15. 0:42Patients come in for surgery with full stomachs,
  16. 0:45vomiting into their lungs while unconscious.
  17. 0:48Rapid weight loss dissolves facial fat and muscle.
  18. 0:50Without support, your skin sags,
  19. 0:52creating the hollowed-out look known as Ozempic face.
  20. 0:56It's a powerful medical tool, not a cosmetic hack.
  21. 0:59Taking it for vanity risks permanent paralysis of your gut.
  22. 1:02Choose wisely.

@health.craft0's Ozempic stomach claims, fact-checked

Health Craft

TikTok creator

69.8K viewsWatch on TikTok

Quick answer

Semaglutide slows gastric emptying as part of its therapeutic mechanism, and clinically significant gastroparesis has been documented as a rare adverse event, with a 2023 JAMA study by Sodhi et al. reporting a meaningfully elevated risk compared to other weight-loss agents. Patients on GLP-1 receptor agonists face documented aspiration risk under general anesthesia due to delayed gastric emptying, prompting 2023 ASA guidance recommending pre-operative medication holds. The video's framing of gastroparesis as a common or permanent outcome is not supported by current evidence, and patients with concerns should consult their prescriber rather than adjusting or stopping medication independently.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @health.craft0's Ozempic stomach claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@health.craft0's Ozempic stomach claims, fact-checked" from Health Craft. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide slows gastric emptying as part of its therapeutic mechanism, and clinically significant gastroparesis has been documented as a rare adverse event, with a 2023 JAMA study by Sodhi et al.

The reason this review is not generic is the source wording and the canonical claim label "glp1 what happens to your stomach on ozempic 3danimation whath." In this clip, the useful excerpt is: "It's the most viral weight loss drug in history." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The American Society of Anesthesiologists issued 2023 guidance recommending patients hold weekly GLP-1 drugs for one week before elective surgery due to aspiration risk from delayed gastric emptying.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide slows gastric emptying as part of its therapeutic mechanism, and clinically significant gastroparesis has been documented as a rare adverse event, with a 2023 JAMA study by Sodhi et al.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide slows gastric emptying as part of its therapeutic mechanism, and clinically significant gastroparesis has been documented as a rare adverse event, with a 2023 JAMA study by Sodhi et al. reporting a meaningfully elevated risk compared to other weight-loss agents. Patients on GLP-1 receptor agonists face documented aspiration risk under general anesthesia due to delayed gastric emptying, prompting 2023 ASA guidance recommending pre-operative medication holds. The video's framing of gastroparesis as a common or permanent outcome is not supported by current evidence, and patients with concerns should consult their prescriber rather than adjusting or stopping medication independently.
  • The Sodhi et al. 2023 JAMA study found a roughly 9x higher risk of gastroparesis with GLP-1 agonists versus bupropion-naltrexone in a diabetes/obesity population, but absolute rates remain low for most patients.
  • The American Society of Anesthesiologists issued 2023 guidance recommending patients hold weekly GLP-1 drugs for one week before elective surgery due to aspiration risk from delayed gastric emptying.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The Sodhi et al. 2023 JAMA study found a roughly 9x higher risk of gastroparesis with GLP-1 agonists versus bupropion-naltrexone in a diabetes/obesity population, but absolute rates remain low for most patients.
  • The American Society of Anesthesiologists issued 2023 guidance recommending patients hold weekly GLP-1 drugs for one week before elective surgery due to aspiration risk from delayed gastric emptying.
  • Sulfur-smelling burps are a reported side effect of slowed digestion but do not indicate food is literally decomposing in your stomach in healthy patients.
  • Bezoars, hardened masses from undigested food, are a documented complication of severe gastroparesis but are rare and not a typical outcome for people on semaglutide.
  • There is no current clinical evidence that semaglutide causes permanent gastroparesis in otherwise healthy patients; the 'permanent paralysis' claim in this video is not supported by the literature.
  • Facial volume changes associated with semaglutide use are driven by overall caloric deficit and fat loss, not a specific drug action on the face, and occur with any significant rapid weight loss.
  • If you experience persistent nausea, bloating, or vomiting of undigested food while on a GLP-1 agonist, contact your prescriber. Do not stop or adjust your dose based on a TikTok video.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @health.craft0 actually say?

The video claims semaglutide "can paralyze your stomach, leaving food to rot inside you" and that this causes "sulfur gas and hardened rocks" to form. It also says gastroparesis is a known risk, that patients are showing up to surgery with full stomachs and vomiting into their lungs, and that "Ozempic face" comes from rapid fat and muscle loss. The video closes with a warning that using the drug "for vanity risks permanent paralysis of your gut."

That's a lot of claims packed into a short video. Some of them are grounded in real pharmacology. Others are exaggerated to the point of being misleading. And the framing, specifically the word "rot," is designed to frighten rather than inform.

Does the science back this up?

Partly. The basic mechanism is accurate: semaglutide does slow gastric emptying, and gastroparesis is a documented risk. But the claim that food "rots inside you" for days is an overstatement of how gastric delayed emptying actually works in most patients.

Semaglutide acts on GLP-1 receptors in the gut and brain, slowing gastric motility as part of its mechanism. This is not a side effect, it is part of how it works. For most people this causes manageable nausea and fullness. Clinically significant gastroparesis, where the stomach essentially stops emptying, is rare. A 2023 JAMA paper by Sodhi et al. found the risk of gastroparesis was significantly higher with GLP-1 agonists than with bupropion-naltrexone in patients without diabetes, with an adjusted incidence rate ratio of 9.09. That is a real signal. But the absolute risk in the broader population remains low, and the study was in people with diabetes and obesity, limiting generalizability. The video presents an uncommon complication as though it is the expected outcome.

On the anesthesia point, this one is actually well-supported. The American Society of Anesthesiologists issued guidance in 2023 recommending that patients on GLP-1 agonists hold the medication before elective procedures due to aspiration risk from delayed gastric emptying. This is a real clinical concern that deserves more mainstream attention, not less.

What did they get wrong (or right)?

The gastroparesis framing is the biggest problem. The video says "your stomach literally stops moving" and food "sits there for days," implying this is a common or expected outcome. It is not. Most patients experience mild-to-moderate delayed gastric emptying, not paralysis. The word "permanently" in the outro, "permanent paralysis of your gut," is particularly irresponsible. There is no established evidence that semaglutide causes permanent gastroparesis in people who were otherwise healthy before starting it. Most cases of GLP-1-associated gastroparesis have resolved after discontinuation, based on case reports and the Sodhi et al. data.

The "sulfur gas and hardened rocks" language is dramatic but not entirely fabricated. Delayed gastric emptying can cause bacterial fermentation of undigested food, and bezoars, hardened masses of undigested material, are a documented complication of severe gastroparesis. But the video makes it sound like everyone on Ozempic is fermenting food in their stomach, which is false.

Credit where it is due: the anesthesia risk section is accurate and under-reported. The mechanism description, GLP-1 mimicry slowing digestion and signaling satiety, is broadly correct. And the closing line, "it's a powerful medical tool, not a cosmetic hack," is the most responsible thing in the video.

What should you actually know?

Gastroparesis is a real but rare complication. The Sodhi et al. 2023 study in JAMA found a higher risk compared to other weight-loss drugs, but absolute rates remain low. If you are on semaglutide and experiencing persistent nausea, bloating, or vomiting of undigested food, those symptoms warrant a call to your prescriber, not a TikTok scroll.

The anesthesia risk is real and actionable. Tell your surgical team and anesthesiologist that you are on a GLP-1 agonist before any procedure. The ASA 2023 guidance recommends holding weekly GLP-1 drugs for one week before elective surgery. This is not a reason to avoid the medication; it is a reason to communicate with your care team.

  • Sulfur burps are a reported side effect but are caused by slowed digestion and gas buildup, not literal rotting food in healthy patients.
  • "Ozempic face" is a real phenomenon but is primarily driven by rapid overall fat loss, not muscle wasting specific to the face. It is not unique to semaglutide; it happens with any significant caloric deficit.
  • "Permanent paralysis of your gut" from semaglutide in otherwise healthy patients is not supported by current evidence. This claim needs a retraction or at minimum a correction.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Health Craft · TikTok creator

69.8K views on this video

What Happens To Your Stomach On Ozempic? #3DAnimation #WhatHappens #BodyFacts #Shorts #fyp #Science #HealthFacts #Warning #Semaglutide#usa

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the sodhi et al. 2023 jama study found a roughly?

The Sodhi et al. 2023 JAMA study found a roughly 9x higher risk of gastroparesis with GLP-1 agonists versus bupropion-naltrexone in a diabetes/obesity population, but absolute rates remain low for most patients.

What does the video say about the american society of anesthesiologists?

The American Society of Anesthesiologists issued 2023 guidance recommending patients hold weekly GLP-1 drugs for one week before elective surgery due to aspiration risk from delayed gastric emptying.

What does the video say about sulfur-smelling burps?

Sulfur-smelling burps are a reported side effect of slowed digestion but do not indicate food is literally decomposing in your stomach in healthy patients.

What does the video say about bezoars, hardened masses from undigested food,?

Bezoars, hardened masses from undigested food, are a documented complication of severe gastroparesis but are rare and not a typical outcome for people on semaglutide.

What does the video say about there?

There is no current clinical evidence that semaglutide causes permanent gastroparesis in otherwise healthy patients; the 'permanent paralysis' claim in this video is not supported by the literature.

What does the video say about facial volume changes associated with semaglutide use?

Facial volume changes associated with semaglutide use are driven by overall caloric deficit and fat loss, not a specific drug action on the face, and occur with any significant rapid weight loss.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Health Craft, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.